William J. Link Ph.D.
CIK: 0001228684
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (27 total)
- Sep 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct201 shares- - Sep 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct11.7K shares at avg. $78.33$915K - Sep 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct759 shares at avg. $79.00$60K - Sep 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct66 shares at avg. $80.01$5K - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
3.8K shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
806 shares- - Jun 25, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
2.4K shares- - Jun 17, 2026RXST
RxSight, Inc.
Award(A)Direct37K shares- - Jun 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct1.9K shares at avg. $62.94$121K - Jun 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct10.6K shares at avg. $61.97$655K - Jun 12, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct3K shares- - Jun 3, 2026LNSR
LENSAR, Inc.
Award(A)Direct17.4K shares- - Mar 16, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct8.4K shares at avg. $69.03$578K - Mar 16, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct3.6K shares at avg. $68.09$247K - Mar 16, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct493 shares at avg. $69.75$34K - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct5K shares at avg. $80.80$408K - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct6.3K shares at avg. $81.75$516K - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct1.1K shares at avg. $82.39$95K - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Indirect5.7K shares at avg. $80.71$458K - Dec 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Indirect4.8K shares at avg. $81.50$388K - Sep 16, 2025TARS
Tarsus Pharmaceuticals, Inc.
Gift(G)Direct2K shares- - Sep 8, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct27.1K shares at avg. $57.00$1.5M - Jun 13, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct3.4K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
4.5K shares- - Jun 12, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 15, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 201 | - | $0 | Direct |
| Sep 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 11,675 | $78.33 | $914,503 | Direct |
| Sep 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 759 | $79.00 | $59,961 | Direct |
| Sep 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 66 | $80.01 | $5,281 | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 3,837 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 806 | - | - | Direct |
| Jun 25, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,417 | - | - | Direct |
| Jun 17, 2026 |  RXST RxSight, Inc. | Award(A) | 37,037 | - | $0 | Direct |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 1,928 | $62.94 | $121,348 | Direct |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 10,572 | $61.97 | $655,147 | Direct |
| Jun 12, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 2,954 | - | $0 | Direct |
| Jun 3, 2026 |  LNSR LENSAR, Inc. | Award(A) | 17,421 | - | $0 | Direct |
| Mar 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 8,378 | $69.03 | $578,333 | Direct |
| Mar 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 3,629 | $68.09 | $247,099 | Direct |
| Mar 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 493 | $69.75 | $34,387 | Direct |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 5,046 | $80.80 | $407,717 | Direct |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 6,306 | $81.75 | $515,516 | Direct |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 1,148 | $82.39 | $94,584 | Direct |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 5,680 | $80.71 | $458,433 | Indirect |
| Dec 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 4,766 | $81.50 | $388,429 | Indirect |
| Sep 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Gift(G) | 2,000 | - | - | Direct |
| Sep 8, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 27,116 | $57.00 | $1,545,612 | Direct |
| Jun 13, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 3,350 | - | - | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 4,540 | - | - | Direct |
| Jun 12, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 2,954 | - | - | Direct |
1-25 of 27 transactions
About LINK WILLIAM J PHD
LINK WILLIAM J PHD (SEC CIK 0001228684) files insider reports with the SEC as Director of Tarsus Pharmaceuticals, Inc. (TARS), Director of RxSight, Inc. (RXST) and Director of LENSAR, Inc. (LNSR).
Signal8 holds 13 ownership filings by LINK WILLIAM J PHD, all Form 4s, filed between May 28, 2025 and Sep 17, 2026. Those filings report 27 transactions, from May 23, 2025 to Sep 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on LINK WILLIAM J PHD's filings is in IRVINE, CA.
Recent filings by LINK WILLIAM J PHD
- Sep 15, 2026: Option exercise of TARS shares (Form 4, code M).
- Sep 15, 2026: Open-market sales of TARS shares (3 lines, Form 4, code S).
- Jun 25, 2026: Grants or awards of TARS derivative securities (3 lines, Form 4, code A).
- Jun 17, 2026: Grant or award of RXST shares (Form 4, code A).
- Jun 15, 2026: Open-market sales of TARS shares (2 lines, Form 4, code S).
Other insiders filing for Tarsus Pharmaceuticals, Inc. (TARS)
- PYOTT DAVID E I, Director
- YARNO WENDY L, Director
- Azamian Bobak R., President/CEO and Board Chair
- Lin Elizabeth Yeu, Chief Medical Officer
- Neervannan Seshadri, Chief Operating Officer
- Goodrich Katherine, Director